AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02873806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye
Study NCT04217174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Personal Health Guide
Description: My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
Study NCT04217174 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: My Personal Food Guide
Description: My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
Study NCT01100931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days.
Study NCT01100931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under curve (AUC) of 6 intravenous on day 1
Study NCT01100931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 intravenous on day 1
Study NCT00201682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 25 mg SQ twice weekly weeks 1-5
Study NCT00201682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: (375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
Study NCT01694849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Study NCT01694849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 120mg
Study NCT01814501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01814501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01814501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01839552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Nasal Spray (FCNS)
Study NCT02775344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimension laparoscopy
Description: Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
Study NCT04339400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105
Description: TQ05105 is a JAK2 inhibitor.
Study NCT01694849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03695471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00577382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT03303144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: ferric pyrophosphate citrate
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Any prophylaxis for GVHD
Description: Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
Study NCT03225417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any prophylaxis for GVHD
Description: Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
Study NCT04092140 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: easy new non invasive tool
Study NCT03595956 — intervention group
Intervention type: OTHER
Intervention: Medical gender affirmation
Description: The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
Study NCT00033397 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Study NCT00033397 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Study NCT00033397 — intervention group
Intervention type: PROCEDURE
Intervention: radiomammography
Study NCT00033397 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound imaging
Study NCT00033397 — intervention group
Intervention type: RADIATION
Intervention: gadopentetate dimeglumine
Study NCT00033397 — intervention group
Intervention type: DRUG
Intervention: chemotherapy
Study NCT02692859 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib conjugate vaccine
Description: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
Study NCT02502188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90005
Study NCT02502188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03730064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Description: Experimental medication with N-acetyl cysteine (NAC) for six weeks
Study NCT01655368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapeutic STEM modules
Description: psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
Study NCT01655368 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interventional control of normal psychoeducational treatment
Description: 11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
Study NCT04348032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD 40mg/m2 ivgtt q4w
Description: The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
Study NCT02434419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Description: The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
Study NCT02434419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific training
Description: Patients underwent specific training exercises to improve pectoral fitness.
Study NCT02434419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific training
Description: Patients underwent specific training exercises to improve pectoral fitness.
Study NCT01623375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
Study NCT01623375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
Study NCT03158441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast MRI
Description: comparison of DTI to dynamic MRI
Study NCT02028052 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ROSE
Description: The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
Study NCT04693286 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: novel oral polio type 2 vaccine (nOPV2)
Description: • nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
Study NCT04693286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active ingradients, only sucrose in buffer
Study NCT04346836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity, general-fitness exercises
Description: 24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination.
Study NCT04346836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
Study NCT03650140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry extract 60 mL
Description: Subjects will receive a single 60 mL oral dose of tart cherry extract.
Study NCT03650140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart cherry extract 120 mL
Description: Subjects will receive a single 120 mL oral dose of tart cherry extract.
Study NCT01350128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 7 days
Study NCT02028052 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 22 gauge Vizishot needles
Study NCT02567721 — intervention group
Intervention type: OTHER
Intervention: Vaccine safety surveillance
Description: Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
Study NCT00971100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study NCT01258023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad 1x
Description: 15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml
Study NCT02702180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
Study NCT02702180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebulizer solution for inhalation
Study NCT02702180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system
Study NCT02702180 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system
Study NCT03877302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology
Description: foot reflexology
Study NCT03646474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic Acid infusion
Description: The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
Study NCT03646474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
Study NCT04086199 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar discectomy
Description: Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
Study NCT01184924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Arthritis Foundation Tai Chi Program
Description: The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
Study NCT02352753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous (SC) injection.
Study NCT04120272 — intervention group
Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
Study NCT04345679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
Study NCT00607867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LoBAG30 diet
Description: A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
Study NCT00607867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
Study NCT04130672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy
Description: After hot packing nasopharyngeal irrigation with 50 C saline
Study NCT04130672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy
Description: After cold packing nasopharyngeal irrigation with 22 C saline
Study NCT03005548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins.
Study NCT03005548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning.
Study NCT03005548 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine
Description: In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning.
Study NCT04361578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance elastography
Description: All patients enrolled will receive magnetic resonance elastography of the brain.
Study NCT03962075 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic paravaginal repair
Description: Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
Study NCT00126776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: case management
Description: case/self management for COPD vs usual care
Study NCT00126776 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: usual care for COPD
Study NCT00479856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule tyrosine kinase inhibitor
Study NCT00479856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy
Study NCT00479856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy
Study NCT00479856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Chemotherapy
Study NCT01749150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir + ritonavir
Description: 125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
Study NCT01749150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir + ritonavir
Description: 125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
Study NCT01749150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 12 weeks
Study NCT01749150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks
Study NCT01749150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000-1200 mg orally daily in divided doses, 12 weeks
Study NCT01749150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000-1200 mg orally daily in divided doses, 24 weeks
Study NCT04611087 — intervention group
Intervention type: BEHAVIORAL
Intervention: Discussion
Description: Attend focus groups
Study NCT04611087 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Attend interviews
Study NCT04611087 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies